ArticlePituitary2011
Temozolomide for corticotroph pituitary adenomas refractory to standard therapy.
Article in Pituitary, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- Effect of antineoplastic drug therapies on carcinoma and aggressive pituitary tumors: a systematic review and meta-analysis.Pituitary · 2025Pooled it
- Aggressive and malignant pituitary tumours: does the sex matter?Pituitary · 2026Review
- Current and Emerging Pharmacological Therapies for Cushing's Disease.Current pharmaceutical design · 2024Review
- Pharmacological management of severe Cushing's syndrome: the role of etomidate.Therapeutic advances in endocrinology and metabolism · 2022Review
- Review
- A Consensus Statement on acromegaly therapeutic outcomes.Nature reviews. Endocrinology · 2018Review
- Pituitary-Directed Therapies for Cushing's Disease.Frontiers in endocrinology · 2018Review
- New Insights in Cushing Disease Treatment With Focus on a Derivative of Vitamin A.Frontiers in endocrinology · 2018Review
- A Rapid Biochemical and Radiological Response to the Concomitant Therapy with Temozolomide and Radiotherapy in an Aggressive ACTH Pituitary Adenoma.Case reports in endocrinology · 2017Article
- Temozolomide treatment of pituitary carcinomas and atypical adenomas: systematic review of case reports.Neuro-oncology practice · 2016Article
- Role of "old" pharmacological agents in the treatment of Cushing's syndrome.Journal of endocrinological investigation · 2016Review
- Temozolomide for aggressive ACTH pituitary tumors: failure of a second course of treatment.Pituitary · 2016Article
- Review
- Medical combination therapies in Cushing's disease.Pituitary · 2015Article
- Clinical Guidelines for the Diagnosis and Treatment of Cushing's Disease in Korea.Endocrinology and metabolism (Seoul, Korea) · 2015Review
- Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center.Journal of neuro-oncology · 2015Article
- Temozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina.International journal of endocrinology · 2015Article
- Temozolomide-Induced Shrinkage of Invasive Pituitary Adenoma in Patient with Nelson's Syndrome: A Case Report and Review of the Literature.Case reports in endocrinology · 2015Article
- Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide.Medical molecular morphology · 2014Review
- Recent advances in the medical treatment of Cushing's disease.F1000prime reports · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To highlight the potential of temozolomide (TMZ) to induce rapid tumor regression in patients with aggressive corticotroph adenomas (CA) that are refractory to surgery and radiation therapy and to review use of TMZ in other pituitary tumors. We present a case of a 56-year-old male with a 3 cm CA treated with transphenoidal surgery (TSS) and conventional radiotherapy in the same year. His hypercortisolemia recurred 11 years later with rapid tumor growth (to 4.2 × 2.5 cm) and he underwent a second TSS with good resection. The tumor recurred 6 months later with ophthalmoplegia. Over 16 months he underwent an additional three surgeries (two TSS, one craniotomy) and repeated conventional radiotherapy. Ki67 staining index on surgical specimens was 5-6%. Temozolomide is an oral alkylating agent approved for glioblastoma multiforme treatment that has only recently shown promise in treating some pituitary tumors. In this patient TMZ was started at 150 mg/m²/day, titrated to 200 mg/m²/day, taken 5 days per month. The only significant side effect was moderate nausea. After 10 weeks, the tumor showed a remarkable 60% regression with objective improvement in ophthalmoplegia. Treatment of aggressive CAs represents a therapeutic challenge and in some cases surgical debulking and radiotherapy are of limited success. Few reports of CAs responsive to TMZ have been reported in the literature. To our knowledge, this case represents the most rapid robust CA shrinkage response reported to date. Further randomized clinical trials of TMZ in the treatment of aggressive pituitary adenomas are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.